Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices

Anna Del Mazo-Barbara, Clémentine Mirabel, Valentín Nieto, Blanca Reyes, Joan García-López, Irene Oliver-Vila, Joaquim Vives

Research output: Contribution to journalArticleResearchpeer-review

Abstract

© 2016 Future Medicine Ltd. Aim: Computerized systems (CS) are essential in the development and manufacture of cell-based medicines and must comply with good manufacturing practice, thus pushing academic developers to implement methods that are typically found within pharmaceutical industry environments. Materials & methods: Qualitative and quantitative risk analyses were performed by Ishikawa and Failure Mode and Effects Analysis, respectively. Results: A process for qualification of a CS that keeps track of environmental conditions was designed and executed. The simplicity of the Ishikawa analysis permitted to identify critical parameters that were subsequently quantified by Failure Mode Effects Analysis, resulting in a list of test included in the qualification protocols. Conclusion: The approach presented here contributes to simplify and streamline the qualification of CS in compliance with pharmaceutical quality standards.
Original languageEnglish
Pages (from-to)521-528
JournalRegenerative Medicine
Volume11
Issue number6
DOIs
Publication statusPublished - 1 Sep 2016

Keywords

  • academic institution
  • cell therapy
  • computerized system
  • Failure Mode Effects Analysis
  • good manufacturing practice
  • Ishikawa
  • qualification
  • validation

Fingerprint Dive into the research topics of 'Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices'. Together they form a unique fingerprint.

  • Cite this